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Deterioration of lung function is the most frequent cause
of death in SSc. Alveolitis is considered the initiating
event of SSc lung fibrosis. Effective therapy of SSc
alveolitis is, therefore, of paramount importance. Here
we assessed the use of intravenous CYC on pulmonary
function testing(PFT) and high resolution computerized
tomography (HRCT) abnormalities in 15 patients with
SSc and alveolitis.
Methods
Fifteen patients with SSc and alveolitis diagnosed by
clinical, bronchoalveolar lavage, or HRCT findings were
treated with intravenous pulse CYC (750 mg/m2 of body
surface area) monthly for 6 months. If there was no
improvement on PFT or HRCT findings, patients were
continued with 6 monthly pulses. If the condition was
stable or improved, patients received 3 additional
bimonthly pulses. After the first year, patients continued
with CYC pulses every 3 months for one year. PFT and
HRCT of the chest were obtained during and following
therapy to determine the efficacy of CYC treatment.
Seven patients received low-dose oral corticosteroids for
reasons other than interstitial lung disease.
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Results
A regression analysis was performed after normalizing
the DLCO (diffusion capacity of the lung for carbon
monoxide), FVC (forced vital capacity), and TLC (total
lung capacity) values to the values obtained immediately
prior to initiation of treatment. This analysis revealed a
61% improvement in the DLCO at 36 months,
following initiation of CYC therapy. The FVC and the
TLC improved by 28% and 27%, respectively, during
the same period. These results were in contrast to a 35%
decline in DLCO during the 36 months prior to therapy.
FVC and TLC were essentially unchanged in the pretreatment period. HRCT showed improvement in the
ground glass appearance in 80% of the cases, while 20%
were unchanged. Fibrosis improved in 67% and
remained unchanged in 33%. Honeycombing, if present,
disappeared in every case.
Conclusion
Intravenous pulse CYC treatment alone or accompanied
by low dose corticosteroid therapy was an effective and
well tolerated treatment of SSc inflammatory lung
disease. The greatest improvement was observed in
DLCO, although there was improvement in FVC and
TLC values, as well.

